7Baggers
 Forsta AP Fonden Acquires Shares of 156,252 CureVac N.V. $CVAC  MarketBeat Mon, 17 Nov 2025 09:44:03 GMT
 CureVac’s Strategic Pivot Delivers Financial Turnaround  AD HOC NEWS Mon, 17 Nov 2025 05:00:05 GMT
 curevac investors face pivotal merger decision  AD HOC NEWS Fri, 14 Nov 2025 17:27:03 GMT
 published on: 2025-11-13 06:05:55  newser.com Thu, 13 Nov 2025 12:05:55 GMT
 curevac acquisition nears critical shareholder vote  AD HOC NEWS Thu, 13 Nov 2025 02:51:04 GMT
 critical weeks ahead for curevac shareholders  AD HOC NEWS Wed, 12 Nov 2025 05:13:04 GMT
 curevac investors face pivotal acquisition decision  AD HOC NEWS Tue, 11 Nov 2025 18:26:04 GMT
 curevac investors face pivotal acquisition vote and earnings report  AD HOC NEWS Mon, 10 Nov 2025 18:57:05 GMT
 published on: 2025-11-10 04:00:14  newser.com Mon, 10 Nov 2025 10:00:14 GMT
 CureVac is Now Oversold (CVAC)  Nasdaq Fri, 07 Nov 2025 17:27:00 GMT
 critical week ahead for curevac as key events converge  AD HOC NEWS Thu, 06 Nov 2025 03:14:03 GMT
 CureVac (CVAC) Projected to Post Quarterly Earnings on Tuesday  MarketBeat Wed, 05 Nov 2025 08:00:00 GMT
 curevac shareholders face critical acquisition deadline  AD HOC NEWS Wed, 05 Nov 2025 03:19:04 GMT
 Regeneron and CureVac: UPC ‘cannot be ignored’  Life Sciences Intellectual Property Review Tue, 04 Nov 2025 22:20:07 GMT
 curevac shareholders face pivotal acquisition vote  AD HOC NEWS Mon, 03 Nov 2025 16:19:04 GMT
 curevac’s strategic shift delivers stunning financial turnaround  AD HOC NEWS Sun, 02 Nov 2025 04:14:04 GMT
 curevac announces extraordinary meeting for merger with biontech  The Globe and Mail Tue, 28 Oct 2025 10:42:00 GMT
 curevac investors face critical share exchange decision  AD HOC NEWS Mon, 27 Oct 2025 17:54:04 GMT
 curevac schedules extraordinary shareholder meeting for november 25  Investing.com Mon, 27 Oct 2025 07:00:00 GMT

CureVac N.V
(NASDAQ:CVAC) 

CVAC stock logo

CureVac N.V., a clinical-stage biopharmaceutical company, engages in developing various transformative medicines based on messenger ribonucleic acid (mRNA). Its lead proprietary programs include CV8102 that is in a Phase 1 dose escalating clinical trials for four types of cancers as a monotherapy an...

Founded: 2000
Full Time Employees: 500
CEO: Franz-Werner Haas  
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends